Clinical trials: Androgens
Prostate Cancer
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00024232
- Testing
- monoclonal antibody huJ591
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer, Sarcopenia
Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy
This randomized, double-blind, placebo-controlled clinical trial will investigate the effects of creatine supplementation combined with a 12-week supervised resistance training program on muscle mass, muscle strength, physical…
- Trial name
- NCT07463092
- Testing
- Creatine Monohydrate, Maltodextrin, Resistance training
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- University of Sao Paulo
Prostate Cancer
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
- Trial name
- NCT04631744
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Salivary Gland Neoplasm Duct
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma…
- Trial name
- NCT06348264
- Testing
- Rezvilutamide, Leuprolide Acetate
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Peking University First Hospital
Breast Cancer, Metastasis
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
- Trial name
- NCT05095207
- Testing
- Abemaciclib, Bicalutamide
- Where
- 3 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Sarcopenia, Prostate Cancer
Changes in Body Composition With Patients Under Androgen Deprivation Therapy
This study aimed to evaluate the correlation of change in body composition and oncological outcomes of prostate cancer patients under androgen deprivation therapy(ADT).
- Trial name
- NCT04037488
- Testing
- Inbody 320
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Seoul National University Hospital
Adenocarcinoma of the Prostate, Stage III Prostate Cancer
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT00003517
- Testing
- antineoplaston A10, antineoplaston AS2-1, bicalutamide
- Where
- United States
- Sponsor
- Burzynski Research Institute
Prostate Cancer
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
The goal of this clinical research study is to learn if ipilimumab in combination with either Lupron® (leuprolide), Zoladex® (goserelin), or Firmagon® (degarelix) can affect prostate-specific antigen (PSA) levels in patients with…
- Trial name
- NCT01377389
- Testing
- Ipilimumab, Leuprolide, Goserelin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
Primary objectives: To determine the maximum tolerated doses (MTDs) of daily lenalidomide and docetaxel given every three weeks and prednisone, as combination therapy to subjects with androgen independent prostate cancer To…
- Trial name
- NCT01378091
- Testing
- Lenalidomide, Docetaxel, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Columbia University
Prostate Cancer, Malignant Neoplasm of Prostate
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment.
- Conditions
- Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
- Trial name
- NCT06150417
- Testing
- Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
This prospective, single center, phase II study is to evaluate the efficacy and safety of bicalutamide as a treatment in androgen receptor (AR)-positive metastatic triple-negative breast cancer (mTNBC) patients.
- Trial name
- NCT02348281
- Testing
- Bicalutamide
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
The primary efficacy analysis will be the clinical benefit at 6 months as measured by a modified Response Evaluation Criteria in Solid Tumors RECIST classification.
- Trial name
- NCT01616758
- Testing
- GTx-024 9mg
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- GTx
Prostate Carcinoma, Recurrent Prostate Carcinoma
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD)…
- Trial name
- NCT07202247
- Testing
- Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Polycystic Ovary Syndrome, Estro-progestin Drugs
Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.
The estrogenic component of estro-progestin (EP) is responsible for a negative impact on the metabolic and lipid assessment in women with polycystic ovary syndrome (PCOS).
- Trial name
- NCT01519401
- Testing
- 3 mg drospirenone and 20 µg ethinyl-estradiol, 3 mg drospirenone and 30 µg ethinyl-estradiol
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Catholic University of the Sacred Heart
Hyperandrogenemia, Obesity
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction
This study will test whether longer-term suppression of adrenal function can ameliorate androgen (male hormone) overproduction in overweight early pubertal girls with androgen excess.
- Conditions
- Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
- Trial name
- NCT01422733
- Testing
- Hydrocortisone, dexamethasone, Cosyntropin
- Where
- United States
- Sponsor
- University of Virginia
Sarcopenia, Prostate Cancer
Identifying Fundamental Mechanisms of Skeletal Muscle Ageing in Older Men Undergoing Androgen Deprivation Therapy: a Feasibility Study
To find out whether it is possible to run a study looking at the underlying markers of ageing in muscle quality and quantity in men receiving Androgen Deprivation Therapy for prostate cancer treatment.
- Conditions
- Sarcopenia, Prostate Cancer, Muscle Atrophy, Androgen Deprivation Therapy
- Trial name
- MASS-ADT (NCT07134439)
- Volunteers
- 20 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Aplastic Anemia
Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole
The clinical symptoms of non transfusion dependent non severe aplastic anemia (NSAA) are often lighter than that of severe aplastic anemia.
- Trial name
- NCT03218657
- Testing
- levamisole hydrochloride, Androgens, Cyclosporins
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Shengyun Lin
Spinal Cord Injury, Spinal Cord Injuries
Testosterone Plus Finasteride Treatment After Spinal Cord Injury
The purpose of this study is to determine whether testosterone plus finasteride treatment will improve musculoskeletal health, neuromuscular function, body composition, and metabolic health in hypogonadal men who have experienced…
- Conditions
- Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injuries
- Trial name
- NCT02248701
- Testing
- Testosterone Enanthate, Finasteride
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- VA Office of Research and Development
Metastatic Cancer, Prostate Cancer
Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen blockade therapy may lessen the amount of androgens made by the body. Zoledronic acid may help relieve some of the symptoms caused by bone metastasis.
- Trial name
- ZAPCA (NCT00685646)
- Testing
- antiandrogen therapy, zoledronic acid
- Where
- Japan
- Volunteers
- 227 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Prostate Cancer
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve.
- Trial name
- NCT00654186
- Testing
- Revlimid
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Oncology Specialists, S.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.